Food and snack companies may feel the most pressure as weight-loss drugs become more mainstream and impact consumer behaviors, according to Bank of America. Diabetes drugs that mimic gut hormones such as glucagon-like peptide-1, or GLP-1, have found new audiences in people looking to lose weight. In some instances, people taking these medicines have reported less of a hankering for unhealthy foods or alcohol and other drinks.
Pro compiled some of the stocks that could be at risk that the firm is watching. All data is from LSEG and current as of Friday morning: — 's Michael Bloom contributed to this report
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Higher rates are killing the clean energy stocks—BofA says these are worth buyingBank of America is eyeing these renewable stocks to ride out turmoil in the sector.
Leer más »